Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
Posted 30 April 2012 | By
After being backed by a US Food and Drug Administration (FDA) advisory committee, life sciences manufacturer Johnson & Johnson (J&J) has won FDA approval for Levaquin (levofloxacin), an antibiotic intended to treat pneumonic plague.
The drug's approval is notable because it utilizes a rarely-used approval pathway known as the 'Animal Rule' pathway. The pathway allows sponsors of products intended to treat very dangerous or contagious conditions to forgo clinical trials and instead test the products on human analogues such as monkeys or pigs.
"The FDA approved Levaquin for plague after tests on African green monkeys infected with the bacteria in a lab found 94% of the monkeys given Levaquin survived," reports The Associated Press.
None of the animals given a placebo survived, noted Med Page Today.
Levaquin is manufactured by J&J subsidiary Jenssen Pharmaceuticals.
Med Page Today - Levaquin OK'd to Treat Plague
PharmaPro - FDA Approves Antibiotic to Treat, Prevent Plague
Med City News - FDA approves Levaquin to combat pneumonic plague bioterrorist attack
Regulatory Focus - FDA Close to Approving J&J Drug Via Animal Rule Pathway
Tags: Pneumonic, Plague, JNJ, Levaquin, Animal, J&J, Animal Rule, Johnson & Johnson, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.